tiprankstipranks
Plus Therapeutics (PSTV)
NASDAQ:PSTV
US Market
PSTV
Plus Therapeutics
RESEARCH TOOLSreports
Want to see PSTV full AI Analyst Report?

Plus Therapeutics (PSTV) Earnings Dates, Call Summary & Reports

1,728 Followers

Earnings Data

Report Date
Aug 19, 2026
After Close (Confirmed)
Period Ending
2026 (Q2)
Consensus EPS Forecast
-0.88
Last Year’s EPS
0.5
Same Quarter Last Year
Analyst Consensus
Strong Buy
Based on 3 Analysts Ratings

Earnings Call Summary

Q4 2024
Earnings Call Date:Mar 27, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call presented a mix of promising clinical trial results, successful financing, and strategic acquisitions that position Plus Therapeutics for future growth. However, these positives were offset by an increase in operating loss and a decline in cash reserves. The overall sentiment leans towards optimism due to strong forward-looking developments.
Company Guidance
In the recent Plus Therapeutics' Fourth Quarter and Full Year 2024 Results Conference Call, the company provided extensive guidance on its financial and clinical milestones. The company completed a $15 million equity financing and received $2 million in accelerated grant proceeds from CPRIT, securing funding through mid-2026. Key clinical updates included the completion of the ReSPECT-LM Phase 1 trial, establishing a recommended Phase 2 dose of 44 millicuries for their lead drug REYOBIQ, which showed promising safety and efficacy data. Plus Therapeutics plans to conduct an end-of-Phase 1 meeting with the FDA to finalize the path to approval, especially for LM related to breast cancer. Additionally, the company aims to advance its CNSide diagnostics platform, projecting significant market potential and a planned full launch within the year. Financially, the company reported a net loss of $13 million for 2024, compared to $13.3 million in 2023, and highlighted an expected 2025 grant revenue of $6 to $8 million.
Successful Financing and Partnerships
Plus Therapeutics raised $15 million in an underwritten equity financing and received $2 million in accelerated grant proceeds from CPRIT. This strengthens the balance sheet and provides funding through mid-2026. Partnerships with SpectronRX, IsoTherapeutics, RadioMedix, and ABX were also announced to ensure supply chain management for REYOBIQ.
FDA Approvals and Designations
The company received FDA approval for orphan designation of REYOBIQ for LM due to lung cancer, adding to previous orphan and fast-track designations for breast cancer.
Positive Clinical Trial Results
ReSPECT-LM Phase 1 trial showed promising safety and efficacy data, with a recommended Phase 2 dose of 44 millicuries. Results indicated a median overall survival of nine months, compared to the historical four months.
CNSide Platform Acquisition and Launch
Plus Therapeutics acquired CNSide, a CNS cancer testing platform, to increase the market potential of REYOBIQ by 2-4 times. The assay is set to launch commercially this year, starting with a limited geographic introduction.

Plus Therapeutics (PSTV) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced
Daily Earnings Calendar >

PSTV Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Aug 19, 2026
2026 (Q2)
-0.88 / -
0.5―――
Apr 16, 2026
2026 (Q1)
-0.85 / -1.05
-29.7596.47% (+28.70)――
Mar 12, 2026
2025 (Q4)
-0.80 / -0.83
-9.591.22% (+8.67)――
Oct 30, 2025
2025 (Q3)
-0.50 / -1.00
-9.2589.19% (+8.25)――
Aug 14, 2025
2025 (Q2)
-2.25 / 0.50
-11.25104.44% (+11.75)――
May 30, 2025
2025 (Q1)
-6.20 / -29.75
-18.75-58.67% (-11.00)――
Mar 27, 2025
2024 (Q4)
-12.42 / -9.50
-13.7530.91% (+4.25)―
Nov 14, 2024
2024 (Q3)
-14.06 / -9.25
-2563.00% (+15.75)―
Aug 14, 2024
2024 (Q2)
-13.25 / -11.25
-14.7523.73% (+3.50)―
May 15, 2024
2024 (Q1)
-27.25 / -18.75
-52.564.29% (+33.75)―
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

PSTV Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Apr 16, 2026
$5.65$5.95+5.31%
Mar 12, 2026
$7.37$6.25-15.16%
Oct 30, 2025
$13.25$13.57+2.46%
Aug 14, 2025
$13.55$15.70+15.80%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Plus Therapeutics (PSTV) report earnings?
Plus Therapeutics (PSTV) is schdueled to report earning on Aug 19, 2026, After Close (Confirmed).
    What is Plus Therapeutics (PSTV) earnings time?
    Plus Therapeutics (PSTV) earnings time is at Aug 19, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is PSTV EPS forecast?
          PSTV EPS forecast for the fiscal quarter 2026 (Q2) is -0.88.